Follow-up on Subjects, Integrative Data Analysis and Measurement of Viral Antibodies in The Environmental Determinants of Diabetes in The Young Study (TEDDY)

青年糖尿病环境决定因素研究(TEDDY)中的受试者跟踪、综合数据分析和病毒抗体测量

基本信息

  • 批准号:
    10392400
  • 负责人:
  • 金额:
    $ 999.99万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-04-13 至 2024-03-31
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract The University of South Florida is uniquely qualified to conduct the activities specified in this limited competition RFA. The purpose of the RFA is to fund the continuation of the Data Coordinating Center's (DCC's) functions in support of TEDDY subject follow-up and to add funds for studies of viral markers (antibodies) and the integrative analysis of omics data. Competition will be sufficient to attract applications from collaborators with the capability to perform reliable measurements of viral markers, and to make the data available to TEDDY investigators for collaborative, integrative analyses. The proposed Data Coordinating Center activities include: 1) Executing the study protocol for follow-up of TEDDY study participants according to schedules and procedures contained in the study's Manual of Operations and in collaboration with the Clinical Centers at which participants are enrolled and with NIDDK staff. 2) Receiving, managing, and analyzing data obtained from the clinical centers 3). Monitoring of adherence to the research plan by conducting site visits to monitor the quality of record keeping, source documentation and the accuracy of data entry and also for overseeing data quality control. Steering Committee, subcommittee, and external evaluation committee meetings and workshops.4). Providing statistical support, expertise and oversight throughout the study. 5) Providing study- wide communications, dissemination of study materials such as protocols, Manual of Operations, forms or other study documents, and development and maintenance of the web site. 6) Playing a key role in the operational conduct of TEDDY, providing training and technical assistance to the Clinical Centers in performance of the follow-up assessments; assisting in protocol implementation; and working in conjunction with the Clinical Centers and NIDDK staff to oversee all aspects of Clinical Center performance, including timeliness and quality of data and biosample submission. 7) Procurement and administration of subcontracts for laboratory services, including: central human leukocyte antigen laboratory; the autoantibody laboratories, the mRNA laboratories, infectious disease laboratories, and other laboratories as needed. 8) Providing administrative and logistical support services for the TEDDY Study Group including preparation of publications, and organizing periodic meetings for the study group and subcommittees, workshops, and conference calls. 9) Transfer of all biosamples and data to the NIDDK central repositories according to a timeline developed with the NIDDK. and 10) Working closely with the Clinical Centers in a collaborative and interactive manner and serving on the Steering Committee. The solicitation of external collaborators for studies of viral markers and integrative analyses will follow established mechanisms for soliciting and evaluating proposals. The DCC has successfully done this for several core TEDDY labs and this would be the third solicitation for integrative data analysis.
项目摘要/摘要 南佛罗里达大学是唯一有资格开展这项有限竞赛活动的大学 RFA。RFA的目的是为数据协调中心(DCC)职能的继续提供资金 支持Teddy主题的后续行动,并增加对病毒标志物(抗体)和 组学数据的综合分析。竞争将足以吸引以下合作伙伴的申请 能够对病毒标志物进行可靠的测量,并将数据提供给Teddy 调查人员进行协作、综合分析。拟议的数据协调中心活动包括: 1)根据时间表和Teddy研究参与者的随访,执行研究方案 程序包含在研究的操作手册中,并与临床中心合作,网址为 哪些参与者是注册的,以及NIDDK的工作人员。2)接收、管理和分析获得的数据 来自临床中心3)。通过进行现场访问来监测研究计划的遵守情况 记录保存、原始文件的质量和数据录入的准确性,以及监督 数据质量控制。指导委员会、小组委员会和外部评估委员会会议和 工作室。4)。在整个研究过程中提供统计支持、专门知识和监督。5)提供研究-- 广泛交流、传播研究材料,如议定书、操作手册、表格或 其他研究文件,以及网站的开发和维护。6)发挥关键作用 Teddy的业务行为,为#年的临床中心提供培训和技术援助 后续评估的执行情况;协助执行议定书;以及协同工作 与临床中心和NIDDK工作人员一起监督临床中心绩效的方方面面,包括 数据和生物样本提交的及时性和质量。7)分包合同的采购和管理 提供实验室服务,包括:人类白细胞抗原中央实验室、自身抗体实验室、 信使核糖核酸实验室、传染病实验室和其他所需实验室。8)提供 为泰迪研究小组提供行政和后勤支助服务,包括编写出版物, 为研究小组和小组委员会组织定期会议、讲习班和电话会议。9) 根据与NIDDK共同制定的时间表,将所有生物样本和数据转移到NIDDK中央储存库 NIDDK。和10)以协作和互动的方式与临床中心密切合作 在指导委员会任职。邀请外部合作者研究病毒标志物和 综合分析将遵循征求和评价提案的既定机制。DCC已经 成功地为几个核心Teddy实验室完成了这项工作,这将是第三次征集集成数据 分析。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JEFFREY P KRISCHER其他文献

JEFFREY P KRISCHER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JEFFREY P KRISCHER', 18)}}的其他基金

Limited Competition: Continued Follow-up of Subjects and Initiation of a Second Case-control Cohort in The Environmental Determinants of Diabetes in The Young Study (TEDDY)
有限的竞争:在年轻研究中糖尿病的环境决定因素(TEDDY)中继续对受试者进行随访并启动第二个病例对照队列
  • 批准号:
    10398923
  • 财政年份:
    2021
  • 资助金额:
    $ 999.99万
  • 项目类别:
Human gene transfer & macrophage cell transplantation therapy of hereditary PAP (hPAP)
人类基因转移
  • 批准号:
    10403442
  • 财政年份:
    2021
  • 资助金额:
    $ 999.99万
  • 项目类别:
Human gene transfer & macrophage cell transplantation therapy of hereditary PAP (hPAP)
人类基因转移
  • 批准号:
    10179934
  • 财政年份:
    2021
  • 资助金额:
    $ 999.99万
  • 项目类别:
Limited Competition: Continued Follow-up of Subjects and Initiation of a Second Case-control Cohort in The Environmental Determinants of Diabetes in The Young Study (TEDDY)
有限的竞争:在年轻研究中糖尿病的环境决定因素(TEDDY)中继续对受试者进行随访并启动第二个病例对照队列
  • 批准号:
    10227415
  • 财政年份:
    2021
  • 资助金额:
    $ 999.99万
  • 项目类别:
Human gene transfer & macrophage cell transplantation therapy of hereditary PAP (hPAP)
人类基因转移
  • 批准号:
    10702185
  • 财政年份:
    2021
  • 资助金额:
    $ 999.99万
  • 项目类别:
Follow-up on Subjects, Integrative Data Analysis and Measurement of Viral Antibodies in The Environmental Determinants of Diabetes in The Young Study (TEDDY)
青年糖尿病环境决定因素研究(TEDDY)中的受试者跟踪、综合数据分析和病毒抗体测量
  • 批准号:
    10260891
  • 财政年份:
    2020
  • 资助金额:
    $ 999.99万
  • 项目类别:
NIDDK Follow-up on Subjects and Immunological Assessments in The Environmental Determinants of Diabetes In The Young Study (TEDDY) (UC4)
NIDDK 青年糖尿病环境决定因素研究 (TEDDY) (UC4) 中受试者和免疫学评估的后续行动
  • 批准号:
    10088137
  • 财政年份:
    2017
  • 资助金额:
    $ 999.99万
  • 项目类别:
Data Coordinating Center for Type 1 Diabetes TrialNet (UC4)USF: TrialNet UC4-3
1 型糖尿病数据协调中心 TrialNet (UC4)USF:TrialNet UC4-3
  • 批准号:
    9506924
  • 财政年份:
    2017
  • 资助金额:
    $ 999.99万
  • 项目类别:
Multicenter Interventional Lymphangioleiomyomatosis Early Disease Trial (MILED) - DCC
多中心介入性淋巴管平滑肌瘤病早期疾病试验 (MILED) - DCC
  • 批准号:
    10249943
  • 财政年份:
    2016
  • 资助金额:
    $ 999.99万
  • 项目类别:
Multicenter Interventional Lymphangioleiomyomatosis Early Disease Trial (MILED) - DCC
多中心介入性淋巴管平滑肌瘤病早期疾病试验 (MILED) - DCC
  • 批准号:
    9743827
  • 财政年份:
    2016
  • 资助金额:
    $ 999.99万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 999.99万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 999.99万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 999.99万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 999.99万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 999.99万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 999.99万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 999.99万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 999.99万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 999.99万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 999.99万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了